Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of ALZ-801 in Healthy Adults
NCT04585347Phase 1Completed
- Sponsor
- Alzheon, Inc.
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label trial of valiltramiprosate in Alzheimer's disease (AD) (4 arms), sponsored by Alzheon, Inc. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 3 more. Started Sep 2015; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04585347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585347.